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Abstract
Background: A common single nucleotide polymorphism (SNP) of FTO (rs9939609, T/A) is associated with total body
fatness. We investigated the association of this SNP with abdominal and peripheral fatness and obesity-related metabolic
traits in middle-aged men through a broad range of fatness present already in adolescence.
Methodology/Principal Findings: Obese young Danish men (n=753, BMI$31.0 kg/m
2) and a randomly selected group
(n=879) from the same population were examined in three surveys (mean age 35, 46 and 49 years, respectively). The traits
included anthropometrics, body composition, oral glucose tolerance test, blood lipids, blood pressure, fibrinogen and
aspartate aminotransferase. Logistic regression analysis was used to assess the age-adjusted association between the
phenotypes and the odds ratios for the FTO rs9939609 (TT and TA genotype versus the AA genotype), for anthropometrics
and body composition estimated per unit z-score. BMI was strongly associated with the AA genotype in all three surveys:
OR=1.17, p=1.1*10
26, OR=1.20, p=1.7*10
27, OR=1.17, p=3.4*10
23, respectively. Fat body mass index was also
associated with the AA genotype (OR=1.21, p=4.6*10
27 and OR=1.21, p=1.0*10
23). Increased abdominal fatness was
associated with the AA genotype when measured as waist circumference (OR=1.21, p=2.2*10
26 and OR=1.19,
p=5.9*10
23), sagittal abdominal diameter (OR=1.17, p=1.3*10
24 and OR=1.18, p=0.011) and intra-abdominal adipose
tissue (OR=1.21, p=0.005). Increased peripheral fatness measured as hip circumference (OR=1.19, p=1.3*10
25 and
OR=1.18, p=0.004) and lower body fat mass (OR=1.26, p=0.002) was associated with the AA genotype. The AA genotype
was significantly associated with decreased Stumvoll insulin sensitivity index (OR=0.93, p=0.02) and with decreased non-
fasting plasma HDL-cholesterol (OR=0.57, p=0.037), but not with any other of the metabolic traits. However, all significant
results for both body fat distribution and metabolic traits were explained by a mediating effect of total fat mass.
Conclusion: The association of the examined FTO SNP to general fatness throughout the range of fatness was confirmed,
and this association explains the relation between the SNP and body fat distribution and decreased insulin sensitivity and
HDL-cholesterol. The SNP was not significantly associated with other metabolic traits suggesting that they are not derived
from the general accumulation of body fat.
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Introduction
The human body fatness and the extreme phenotype, obesity,
are influenced by both genes and environment as clearly and
consistently demonstrated in multiple family, twin and adoption
studies [1]. Numerous investigations have been undertaken to
further specify these influences. Since the discovery of the leptin
gene in 1994 [2], there has been an intense search for obesity
genes, but with limited success [1,3]. Until recently, the only gene
in which multiple different, but rare variants have been
consistently associated with monogenic fatness is the gene of the
melanocortin receptor 4 (MC4R) but these mutations are
infrequent in the general population [4].
In 1999, a gene was found to be associated with fused-toes in
mice and was named fatso (FTO) [5]. Recently, a human genome-
wide search for type 2 diabetes susceptibility genes identified a
common variant (T/A) with a minor allele frequency of 0.45 in the
first intron of the FTO gene on chromosome 16q12.2 that
predisposes to type 2 diabetes through an effect on BMI in
Caucasians [6–8]. The association was replicated in 13 cohorts
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(p=3*10
235) [6]. The 16% of adults who had the AA genotype
for the FTO rs9939609 weighed about 3 kg more and had a 1.67
fold increased odds of obesity compared with the non-carriers (TT
genotype). In a subset of children aged 9 years, a DEXA scan was
conducted and showed that the A allele was primarily associated
with the size of the fat mass rather than the lean body mass. The
general findings, though with other SNPs in this gene, were
replicated in series of other European populations [7]. Two
following genome-wide association studies confirmed that the
association between FTO and type 2 diabetes was entirely
mediated by the effect of FTO on fatness [8,9]. This discovery of
the consistent association with human fatness has lead to a
changed name of FTO (GenBank accession no.: NT_010498) from
fatso to ‘‘fat mass and obesity associated’’ gene. The function and
pathway of the FTO gene are unknown, but gene expression
profiles show that FTO is expressed in particular in specific parts of
the brain, muscle and adipose tissue [6,7]. However, a recent gene
expression study suggests that intronic FTO SNPs may exert
functional effects through altered expression of FTO mRNA,
particularly in the hypothalamus [10].
We investigate the effects of the FTO rs9939609 on different
abdominal and peripheral fatness phenotypes and obesity-related
metabolic quantitative traits in middle-aged men throughout a
very broad range of fatness present already in their adolescence.
Further, we examine whether fatness associated with the FTO SNP
is related to other related metabolic quantitative traits.
Methods
Study population
The study population consisted of Danish men originally
identified from the mandatory draft board examinations of
approximately 360 000 men at a median age of 19 years in the
metropolitan area of Copenhagen and surrounding counties from
the years 1943–77. Two groups were manually selected in the late
1970’es from this population: one group of all obese men with a
BMI$31 kg/m
2, n=1930, (corresponding to 35 % overweight
according to a national standard scale in use when the obese
sample was identified) and a randomly selected control group
consisting of 1% of all men in the study population, n=3601. The
overall prevalence of obesity as defined was thus 1930/
360,000=0.54 %, which means that all obese were above the
99
th percentile of BMI in this population.
Fatness-related phenotypic information was available from
three subsequent follow-up surveys of subsets of these two groups:
the Copenhagen City Heart Study, 2
nd and 3
rd survey (year 1981–
83 and 1992–94) and the latest follow-up in year 1998–2000. The
criteria for invitation to the follow-up surveys and the participation
have been described previously [11–13], and the number of
participants shows the expected attrition over time (Table 1). In
the present study, the mean ages at the Copenhagen City Heart
Studies were 35 and 46 years, respectively, and the mean age at
the last survey was 49 years. In the present study these three
surveys are therefore labelled S-35, S-46 and S-49, respectively.
Phenotypic assessments were carried out at all three surveys, and
DNA was sampled from blood sample buffy coats at the S-46.
Phenotypic measurements
Table 1 serves descriptive purposes for the three study samples
and lists the fatness measures and obesity-related metabolic
phenotypes available for analysis from S-35, S-46 and S-49, and
the basic statistics (median and range) in the obese and control
groups. Total body fat mass (kg) was assessed by bioimpedance at
S-46 and from the DEXA scan at S-49. Fat body mass index
(FBMI; kg/m
2) was calculated as total body fat mass (kg) divided
by height (m) squared. Intraabdominal adipose tissue (IAAT; cm
2)
was calculated from DEXA scans and anthropometry using the
equation [14]: y=2208.2+4.62 (sagittal diameter, cm)+0.75 (age,
y)+1.73 (waist, cm)+0.78 (trunk fat, %). In S-46 and S-49 sagittal
abdominal diameter (SAD, cm) was measured with the participant
in expiration phase and lying recumbent on an examination table,
as the distance between the top of the examination table and a
horizontally placed spirit level placed above the abdomen at the
level of the iliac crest. Lower body fat mass (LBFM; %) was
calculated from DEXA scans as the fat percentage of lower body
fat mass. All body composition measurements, except for waist and
hip circumference in S-46 are derived from bioimpedance and in
S-49 derived from DEXA-scans. The bioimpedance method has
proved to be reasonably accurate for assessment of body
composition (fat free mass and fat mass) [15] and the present
results are not influenced by the fact that separate prediction
equations are necessary for different ethnic groups [16]. However,
measurement of total body fat by DEXA-scans are more accurate
than by the impedance method [15].
Participants in S-35 and S-46 had non-fasting glucose levels
determined on fresh plasma samples. In the S-49 cohort oral glucose
tolerance tests (OGTT) were conducted but with the exclusion of
individuals with known diagnosed and thereby treated diabetes
(n=10) [11]. Furthermore, we also derived indices of insulin
sensitivity according to Stumvoll [17], Matsuda [18], and the
recentlyrecommendedBIGTT index(BIGTT-SI)[19].Anindexfor
insulin secretion was derived (BIGTT-AIR (acute insulin response)).
For BIGTT-SI and BIGTT-AIR the measurements of plasma
glucose and serum insulin at the time points 0, 30 and 120 minutes
during the OGTT were used. Details on data collections and
measurement of anthropometric and other phenotypic estimates
have been described elsewhere [11,13,20,21].
Molecular genetic analyses
Genotyping of the FTO rs9939609 SNP was performed using
Taqman allelic discrimination (KBiosciences, Herts, UK). Geno-
type data were obtained in more than 97% of the DNA samples
with a genotype error rate of 0.27% based on 1464 duplicate
samples. All genotype groups obeyed Hardy-Weinberg equilibri-
um and the minor allele frequency was 0.41–0.42 in controls and
0.51–0.52 in obese individuals. Molecular genetic analysis,
including genotyping of the FTO SNP rs9939609, was conducted
on 879 controls and 753 cases.
Statistical analysis
In a logistic regression analysis we tested the effect of rs9939309
on having a BMI$31.0 kg/m
2 at the draft board examination
with the TT genotype as the reference group; we found that the
odds ratio (OR) for the TA genotype was 1.21 [0.96–1.52] and for
the AA genotype 2.04 [1.54–2.70]. A likelihood ratio test (LRT)
for an additive co-dominant effect of the gene was LRT=2.76,
p=0.0969, a dominant effect of the gene LRT=16.55, p,0.0001
and a recessive effect of the gene LRT=2.62, p=0.1052. On basis
of these tests, which show that a recessive model is most
compatible with our data, we have chosen a recessive transmission
mode for the present analyses (TT and TA genotype versus AA
genotype). In order to properly take into account the sampling
design, the two groups of obese and controls have been analysed
together, but separately for each follow-up survey S-35, S-46 and
S-49. Thus, the massive enrichment of the right tail of the BMI
distribution implies that the data cannot be analysed with BMI or
BMI-associated outcomes as response variables in common
FTO, Fatness and Metabolism
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statistical power and much wider coverage of the phenotypes by
keeping the obese and non-obese groups in the analysis, we
reversed the statistical models for the associations and examined
the probability of the particular genotypes for a given level of the
phenotypes. This can be done without distributional assumptions
about the phenotypes. Hence, logistic regression analysis was used
to assess the odds ratios of the genotype (response variable) in
relation to the phenotypes (covariates) in the combined case and
control groups. The response variable was the AA genotype versus
AT and TT genotypes. The other covariates were each phenotype
as measured at each of the follow-up surveys (table 1) with and
without adjustment for the concurrent FBMI (kg/m
2). Information
for FBMI was not available in S-35 and therefore we adjusted for
BMI in these analyses.
To obtain similar fatness units, all anthropometrics and body
composition measures were converted to age-adjusted z-scores,
which indicate the deviations from the population mean values in
standard deviation (SD) units. The age-adjusted z-scores were
calculated from the mean values and SD of the randomly selected
control group and applied to the entire study population. This
conversion into z-scores enables us to directly compare the
strength of the association between the genotype and the various
fatness phenotypes. In the remainder analyses, age at examination
was included as covariate. Smoothing splines with 5 degrees of
freedom in general additive models (GAM) were used to assess and
test for linearity. Significance level was accepted at p,0.05.
Analyses were carried out with SAS statistical procedures (version
9.1; SAS Institute Inc, Cary, NC) and STATA (version 9.2; Stata
Corporation, College Station, Texas).
Ethics
The Danish surveillance Agency and the regional Ethical
Committee approved the study to be in accordance with the
Helsinki Declaration II. All participants signed a written consent
before participating.
Table 1. Distribution of age, anthropometrics, metabolic traits and OGTT-derived indices for FTO rs9939609 genotyped
participants given as median and range.
S-35 S-46 S-49*
Variables Obese N=582 Control N=745 Obese N=753 Control N=879 Obese N=231 Control N=320
Age (yrs) 32.0 [22.0–62.0] 36.0 [22.0–62.0] 43.0 [33.2–72.9] 47.0 [33.1–73.3] 47.0 [39.0–64.0] 49.0 [39.0–65.0]
Anthropometrics
BMI (kg/m
2) 33.3 [18.4–54.0] 24.5 [16.3–40.4] 35.0 [19.9–63.7] 25.7 [16.2–45.1] 35.3 [23.2–56.4] 25.7 [17.9–42.9]
FBMI (kg/m
2) - - 12.0 [3.4–32.1] 6.3 [0.35–19.2] 11.7 [3.8–25.7] 5.7 [1.1–15.9]
Waist (cm) - - 116.5 [79.5–183.0] 93.0 [58.0–139.0] 117.0 [88.0–164.0] 93.0 [69.0–127.0]
SAD (cm) - - 27.2 [16.5–52.6] 21.4 [13.8–36.4] 27.3 [18.8; 40.0] 20.8 [15.2; 31.9]
IAAT (cm
2) - - - - 182.8 [46.6–308.7] 104.8 [23.0–226.7]
Hip (cm) - - 113.9 [48.0–165.0] 100.0 [60.0–132.0] 112.0 [92.0; 155.0] 97.0 [74.0; 126.0]
LBFM (%) - - - - 29.1 [12.0; 51.2] 18.6 [4.6; 41.4]
Insulin-glucose related traits
Glucose (mmol/L) 5.9 [3.6–22.5] 5.9 [3.3–22.0] 4.0 [2.1–19.6] 3.2 [1.7–11.9] 5.9 [4.5–19.1] 5.6 [4.3–12.8]
Insulin (pmol/L) - - - - 59.8 [12.0–332.5] 30.5 [6.5–193.0]
C-peptide (mmol/L) - - - - 808 [272–2418] 554 [173–2107]
HbA1C (%) - - - - 5.7 [4.7–11.9] 5.6 [4.4–10.1]
Stumvoll index - - - - 5.2 [213.0–9.5] 8.8 [20.5–11.9]
Matsuda index - - - - 3.6 [0.6–21.1] 6.8 [1.3–32.4]
BIGTT- SI ----1 . 3 [ 23.7–2.5] 2.1 [20.4–2.8]
BIGTT-AIR - - - - 7.8 [2.8–10.2] 7.4 [5.1–8.7]
Other metabolic traits
Cholesterol (mmol/L) 5.1 [2.3–8.5] 5.1 [3.0–10.1] 5.9 [1.7–21.8] 6.1 [3.2–17.8] 5.5 [2.4–8.7] 5.7 [3.6–9.8]
Triglycerides (mmol/L) - - - - 1.6 [0.6–13.2] 1.2 [0.4–8.0]
HDL (mmol/L) 0.9 [0.3–1.8] 1.0 [0.3–2.1] 1.1 [0.3–3.0] 1.4 [0.5–3.9] 1.0 [0.5–2.0] 1.2 [0.6–2.4]
FFA (mmol/L) - - - - 0.4 [0.1–1.1] 0.4 [0.1–0.9]
Fibrinogen (g/L) - - 320.0 [3.0–858.0] 275.0 [135.0–3004.0] - -
ASAT (IU/L) - - 24.0 [7.0–280.0] 23.0 [3.0–530.0] - -
Systolic BP (mmHg) 138.0 [103.0–213.0] 132.0 [95.0–211.0] 143.0 [103.0–247.0] 136.0 [101.0–219.0] 129.0 [80.0–194.0] 122.0 [90.0–194.0]
Diastolic BP (mmHg) 88.0 [49.0–148.0] 82.0 [47.0–130.0] 95.0 [58.0–151.0] 90.0 [62.0–128.0] 80.0 [57.0–121.0] 76.0 [54.0–114.0]
BMI=body mass index, FBMI=fat body mass index, IAAT=intra-abdominal adipose tissue, SAD=sagittal abdominal diameter, LBFM (%)=lower body fat mass( % ) ,
SAD=Sagittal abdominal diameter, BP=blood pressure, FFA=free fatty acids, BIGTT-SI=OGTT-derived index of insulin sensitivity, BIGTT-AIR=OGTT-derived index of
acute insulin response.
* All values for the S-49 are derived from the OGTT examination and are therefore fasting compared to non-fasting for S-35 and S-46. The
metabolic traits except for BP were derived from plasma blood samples
doi:10.1371/journal.pone.0002958.t001
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Descriptive analysis
The distribution of the FTO rs9939609genotypes were almost
exactly the same at the three surveys indicating that the attrition of
the study groups by time was not dependent on the genotype
(Table 2). There was a linear association with the odds ratio of
being carrier of the FTO rs9939609 AA genotype throughout the
broad range of BMI and FBMI (Figure 1 and 2).
Analysis of fatness
We estimated the odds ratios (OR) of the genotype (response
variable) in relation to the phenotypes (covariates). Results from
logistic regression analyses for fatness phenotypes are given in z-
score odds ratios with 95% confidence intervals. The OR for being
carrier of the AA genotype according to BMI z-score should be
interpreted as an increment in odds for being carrier of the AA
genotype per unit increase in BMI z-score. One z-score unit is
equal to 1 SD of the particular trait in the control sample, and for
the present quantification we have provided the original unit value
for all fatness phenotypes.
TheassociationbetweentheAAgenotypeforrs9939609andBMI
was strongly confirmed in the three surveys at S-35 (OR=1.17,
p=1.1*10
26),S-46 (OR=1.20,p=1.7*10
27) andS-49 (OR=1.17,
p=3.4*10
23) (Table 3). In e.g. S-49 an increase in one unit of
z-score BMI, equivalent to an increase in 3.7 kg/m
2, increased the
odds for the AA genotype by 17%. FBMI was strongly associated
with the AA genotype, as measured by bioimpedance at S-46
(OR=1.21, p=4.6*10
27) and DEXA scan at S-49 (OR=1.21,
p=0.001).
Further, increased abdominal fatness was associated with the
AA genotype measured as waist circumference (OR=1.21,
p=2.2*10
26 and OR=1.19, p=5.9*10
23), sagittal abdominal
diameter (OR=1.17, p=1.3*10
24 and OR=1.18, p=0.011) and
intra-abdominal adipose tissue (OR=1.21, p=0.005). Increased
peripheral fatness measured as hip circumference (OR=1.19,
p=1.3*10
25 and OR=1.18, p=0.004) and LBFM (%)
(OR=1.26, p=0.002) was also associated with the AA genotype.
Analysis of insulin-glucose related traits
The associations between the FTO gene variant, and glucose,
insulin, C-peptide, and HbA1C were not statistically significant
(Table 4).
Except for a decreased Stumvoll index for insulin sensitivity
(OR=0.93, p=0.02) none of the remainder OGTT-derived
indices were significantly associated with the FTO AA genotype.
Albeit not significant, the Matsuda index and the novel BIGTT-SI
test for insulin sensitivity showed similar association as the
Stumvoll index. Insulin release assessed through the novel
BIGTT-AIR test was increased for individuals with the AA
genotype, but only borderline significant (OR=1.36, p=0.08).
Analysis of other metabolic traits
Cholesterol and triglycerides levels were not significantly
associated with the AA genotype. However, a decreased plasma
HDL-cholesterol (OR=0.57 per mmol/L, p=0.037) level was
seen in individuals with the AA genotype when assessed in S-35
(Table 4). Similar associations were seen at following assessments
but with borderline significant results.
Free fatty acids, fibrinogen and ASAT were not significantly
associated with the FTO SNP. Finally, neither systolic nor diastolic
blood pressure was significantly associated with the FTO SNP.
Analysis adjusting for FBMI
The statistical significance of the association between the FTO
genotype and waist circumference, sagittal abdominal diameter,
Figure 1. Smoothing spline (5 degrees of freedom) with 95%
confidence limits of the association between the FTO
rs9939609 AA genotype and BMI (kg/m
2) at S-46 as assessed
by logistic regression with the odds of the AA genotype as the
response variable and the BMI as covariate.
doi:10.1371/journal.pone.0002958.g001
Figure 2. Smoothing spline (5 degrees of freedom) with 95%
confidence limits of the association between the FTO
rs9939609 AA genotype and fat body mass index (FBMI; kg/
m
2) at S-46 as assessed by logistic regression with the odds of
the AA genotype as the response variable and the FBMI as
covariate.
doi:10.1371/journal.pone.0002958.g002
Table 2. Genotype distribution of FTO rs9939609 for controls
and obese participants in S-35, S-46 and S-49, respectively
Survey Controls Obese
TT (%) TA (%) AA (%) MAF TT (%) TA (%) AA (%) MAF
S-35 241
(32.4)
380
(51.0)
124
(16.6)
0.42 140
(24.1)
280
(48.1)
162
(27.8)
0.52
S-46 287
(32.7)
444
(50.5)
148
(16.8)
0.42 192
(25.5)
359
(47.7)
202
(26.8)
0.51
S-49 114
(35.6)
151
(47.2)
55
(17.2)
0.41 61
(26.4)
104
(45.0)
66
(28.6)
0.51
MAF=Minor allele frequency
doi:10.1371/journal.pone.0002958.t002
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insulin sensitivity all vanished when the regression analysis
adjusted the association for FBMI, whereas the association
between the genotype and the FBMI was maintained (Table 5).
Discussion
Results from the present study show that the AA genotype of the
examined SNP in the FTO gene contributes to human fatness
irrespective of adipose tissue distribution. This study adds to
establish the more precise nature of the metabolic effects of the
recently described fat mass and obesity associated gene variant.
Firstly, we have demonstrated associations between FTO
rs9939609 and insulin sensitivity and plasma HDL-cholesterol
levels and secondly, demonstrated that these associations are
explained by the mediating effect of FBMI and thirdly, we imply
that the FTO-related fatness may not be the type of fatness that is
associated with the remainder examined metabolic traits, which
may be dependent on other additional determinants, e.g. genetic
predisposition and chronic inflammation in the adipose tissue.
Table 4. Odds ratio (OR) including 95% confidence intervals (CI) for FTO rs9939609 in relation to metabolic traits and OGTT-
derived indices
Variables S-35 S-46 S-49*
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Insulin-glucose related traits
Glucose (10 mmol/L) 0.88 [0.33; 2.34] 0.79 1.01 [0.97; 1.05] 0.69 0.89 [0.20; 3.97] 0.87
Insulin (50 pmol/L) - - - - 1.08 [0.86; 1.35] 0.49
C-peptide (500 mmol/L) - - - - 1.18 [0.90; 1.54] 0.24
HbA1C (%) - - - - 0.94 [0.71; 1.26] 0.69
Stumvoll index - - - - 0.93 [0.88; 0.99] 0.02
Matsuda index - - - - 0.97 [0.92; 1.02] 0.22
BIGTT-SI - - - - 0.83 [0.67; 1.03] 0.09
BIGTT-AIR - - - - 1.36 [0.97; 1.90] 0.08
Other metabolic traits
Cholesterol (10 mmol/L) 2.29 [0.63; 8.32] 0.21 2.18 [0.94; 5.09] 0.07 2.90 [0.44; 19.2] 0.27
Triglycerides (mmol/L) - - - - 1.05 [0.89; 1.23] 0.56
HDL (mmol/L) 0.57 [0.34; 0.97] 0.037 0.81 [0.60; 1.08] 0.15 0.53 [0.25; 1.10] 0.09
FFA (mmol/L) - - - - 3.02 [0.85; 10.8] 0.09
Fibrinogen (10 g/L) - - 1.01 [1.00; 1.02] 0.11 - -
ASAT (100 IU/L) - - 1.52 [0.83; 2.78] 0.17 - -
Systolic BP (10 mmHg) 0.99 [0.91; 1.09] 0.89 1.02 [0.96; 1.09] 0.56 1.00 [0.89; 1.12] 0.95
Diastolic BP (10 mmHg) 1.01 [0.91; 1.13] 0.79 1.00 [0.90; 1.11] 0.94 1.06 [0.88; 1.28] 0.54
HbA1C=glycated hemoglobin, BIGTT-SI=OGTT-derived index of insulin sensitivity, BIGTT-AIR=OGTT-derived index of acute insulin response
*All values for the S-49 are derived from the OGTT examination and are therefore fasting compared to non-fasting for S-35 and S-46
doi:10.1371/journal.pone.0002958.t004
Table 3. Odds ratio (OR) including 95% confidence intervals (CI) for FTO rs9939609 in relation to fatness phenotypes (in z-scores)
including original unit value of 1 SD
Variables S-35 N=1327 S-46 N=1632 S-49 N=551
Original
unit OR (95% CI) P-value
Original
unit OR (95% CI) P-value
Original
unit OR (95% CI) P-value
z-score of:
BMI (kg/m
2) 3.06 1.17 [1.10; 1.25] 1.1*10
26 3.7 1.20 [1.12; 1.29] 1.7*10
27 3.7 1.17 [1.05; 1.30] 3.4*10
23
FBMI (kg/m
2) - - 2.4 1.21 [1.12; 1.30] 4.6*10
27 2.6 1.21 [1.08; 1.36] 1.0*10
23
Waist (cm) - - 10.5 1.21 [1.12; 1.31] 2.2*10
26 10.7 1.19 [1.05; 1.34] 5.9*10
23
SAD (cm) - - 3.3 1.17 [1.08; 1.27] 1.3*10
24 3.3 1.18 [1.04; 1.34] 1.1*10
22
IAAT (cm
2) - - - - - 38.1 1.21 [1.06; 1.39] 4.7*10
23
Hip (cm) - - 6.8 1.19 [1.10; 1.29] 1.3*10
25 6.8 1.18 [1.05; 1.31] 3.5*10
23
LBFM (%) - - - - - 6.2 1.26 [1.09; 1.45] 1.6*10
23
BMI=body mass index, FBMI=fat body mass index, IAAT=intra-abdominal adipose tissue, SAD=sagittal abdominal diameter, LBFM (%)=lower body fat mass( % )
doi:10.1371/journal.pone.0002958.t003
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association between FTO rs9939609 and BMI throughout its
range. Our results showed a relatively large effect of the genotype
on the examined phenotypes. Thus, the function of FTO appears to
be highly physiologically relevant for the understanding of the
pathogenesis of obesity, and this may also have health-related
significance. For example at S-49, an increase in one unit of z-score
BMI and z-score waist, equivalent to an increase in 3.7 kg/m
2 and
10.7 cm, respectively, was associated with 17–19% increase in odds
for the AA genotype. In a recent large population-based study of
approximately 276,835 children, surprisingly little increase in body
weight throughout the range of body weights was associated with
increases in the risk of coronary heart disease in adulthood [22].
Owing to the sampling design of the obese participants with
massive enrichment of the right tail of the BMI distribution it is
possible to demonstrate a stronger association compared to already
published studies examining the effects of FTO on fatness [6,7].
The present regression analysis with the genotype as response
variable and the phenotypes as covariates may be a limitation,
albeit the analysis strategy is conditional on the strength of the
sampling design. The statistical analysis serves the investigation of
the possible association in occurrence of genotype and phenotype,
and if there is evidence for an association, then the next phase is the
putative causal interpretation, which goes on independent of the
statistical modelling.
Population stratification may occur due to differences in allele
frequencies between cases and controls owing to systematic
differences in ancestry rather than association of genes with the
response variable. However, the fundamental theorem of Hardy-
Weinberg (H-W) law is that in large homogenous, randomly
mating populations the probabilities of H-W law are preserved
from generation to generation and, further in non-homogenous
but randomly mating populations, they are established in a single
generation after mixing [23]. In spite of Denmark being a
relatively small country with only about 5 million inhabitants, we
have no reason to suspect detectable relatedness in our study
population; this is also reflected in the genotype distributions of the
sample, which obeyed H-W equilibrium. The case-cohort study
design of Danish Caucasian men where the controls were
randomly selected from the same population in which the cases
were identified effectively prevents population stratification.
The availability of several repetitive measurements in the same
individuals have given the unique opportunity of analyzing and
comparing a panel of specific fatness phenotypes covering BMI, fat
mass and abdominal and peripheral fatness at different ages. The
samples may seem small for a genetic association study, however,
this apparent limitation of the study is counteracted by the fact
that the control group represents 184 000 men in S-46 and 64 600
in S-49, originally identified at the draft board examination, and
that the obese participants therefore were representing the most
extreme range of the fatness phenotypes in this population at all
three surveys except for the possible effects of selective attrition of
the samples during the follow-up surveys.
The metabolic traits associated with obesity may be inter-
correlated to various extents, but according to a recent twin study
[24], there is little common underlying genetic or shared
environmental etiology behind these correlations, which we think
justifies the separate analysis of each of the traits as we have
conducted here barring the analyses where we examined if the
total body fatness could explain the observed association between
FTO and other traits.
The FTO gene variant appeared to be related to body fat
distribution and some related metabolic phenotypic measures. The
AA genotype was associated with increased abdominal fatness
examined as waist circumference, sagittal abdominal diameter and
intra-abdominal adipose tissue mass. The AA genotype was also
associated with increased peripheral fatness examined as hip
circumference and lower body fat mass. The strength of the
associations between FTO and the various fatness phenotypes was
about equal throughout the range of each phenotype and the
associations vanished when the FBMI was adjusted for by the
regression analysis, suggesting that the effect of the gene variant is
a general increase of the size of the fat mass irrespective of site and
size. Similar results were observed in a study of a Canadian group
of men and women; this group corresponded in size and sampling
frame to our randomly selected control group only, and the study
did not examine if the total fat mass could explain the associations
with the body fat distribution measures [25].
No significant associations were seen between the FTO SNP and
any of the metabolic traits related to the glucose homeostasis
(plasma glucose, insulin, C-peptide, HbA1C, OGTT-derived
indices for insulin sensitivity and release) except for a rather weak
inverse association with the Stumvoll index for insulin sensitivity,
which disappeared when FBMI was adjusted for. This finding was
expected because fatness is inversely correlated with insulin
sensitivity [26]. The abovementioned Canadian study also found
an association between FTO and various measures of insulin
sensitivity, which all vanished when adjusted for BMI [25].
Further, except for the inverse association between plasma
HDL-cholesterol and the AA genotype, no significant associations
were observed for the investigated lipid levels including FFA, liver
function variables or blood pressure. HDL-cholesterol levels were
decreased in all three surveys, though only significantly in S-35.
The present finding is consistent with results from other studies
showing decreased plasma HDL-cholesterol levels commonly
found in obese individuals [27], and also this association vanished
when adjusted for FBMI. The mediating effects of FBMI suggest
that the observed increase in fatness is due to a total increase in fat
mass rather than abdominal fat accumulation. None of the
remainder examined metabolic quantitative traits were associated
with FTO rs9939609.
This implies that the FTO-related fatness does not contribute to
the type of fatness that is associated with these metabolic traits. For
example, for the widely known association between obesity and
blood pressure [13] we did not find a significant association
between rs9939609 and blood pressure. This means that the type of
fatness that rs9939609 causes is not the particular type of fatness
that lead to e.g. increased blood pressure. Nevertheless, we are
Table 5. Odds ratio (OR) including 95% confidence intervals
(CI) for FTO rs9939609 in relation to selected fatness
phenotypes and metabolic traits (adjusted variables) and fat
body mass index (FBMI; kg/m
2) (adjusting variable)
Variables OR (95% CI) P OR (95% CI) P
Adjusted FBMI
Waist (cm) 0.97 [0.75; 1.28] 0.86 1.24 [0.97; 1.57] 0.09
SAD (cm) 0.87 [0.72; 1.06] 0.17 1.34 [1.13; 1.58] 0.0006
Hip (cm) 0.98 [0.83; 1.18] 0.88 1.22 [1.05; 1.43] 0.01
HDL (mmol/L) at S-46 0.98 [0.68; 1.42] 0.92 1.21 [1.11; 1.31] ,0.0001
HDL (mmol/L) at S-49 0.88 [0.39; 1.97] 0.75 1.21 [1.06; 1.37] 0.004
Stumvoll index 1.03 [0.92; 1.15] 0.59 1.29 [1.04; 1.59] 0.02
All variables are given for S-46, except for HDL-cholesterol, which is given for S-
46 and S-49 and Stumvoll index, which is given forS-49.
doi:10.1371/journal.pone.0002958.t005
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narrow, reflecting the statistical power of the study design, the
reported effects sizes attributable to genetic variation may be so
small that we may overlook a true association with a related
metabolic phenotype (type 2 error).
In order to elucidate the effects of the FTO SNP it may be
interesting to assess the impact of the SNP on weight dynamics
throughout life and general growth during childhood and
adolescence. Likewise, the impact of environmental factors (e.g.
physical activity and dietary energy intake) on genetic susceptibil-
ity needs to be further explored [28,29]. In conclusion, results from
the present study show that examined SNP in FTO contributes to
human fatness throughout a very broad range with a correspond-
ing, non-differential effect on adipose tissue distribution. Except
for decreased insulin sensitivity and HDL-cholesterol, which was
explained by the mediating effect of FBMI, the remainder
metabolic quantitative traits were not significantly associated with
FTO rs9939609.
Acknowledgments
This work is part of the project ‘‘Hepatic and adipose tissue and functions
in the metabolic syndrome’’ (HEPADIP, www.hepadip.org). The Authors
wish to thank PhD, Dr. Eva Black for her skilful assistance in collection of
the ADIGEN data used for the present study.
Author Contributions
Analyzed the data: SIIK CH. Wrote the paper: SIIK. Helped in analyzing
data: EZ. Helped in the interpretation of analyses: CH TB EZ TJ. Helped
in the discussion of results: EZ TB TJ. Initiated the study and supervised all
aspects of the study: TS. Contributed with helpful comments and
suggestions: OP TH AA ST. Supervised the molecular genetic aspects of
the study: TH OP. Supervised the physiological aspects of the study: AA
ST CH.
References
1. Clement K, Sørensen TIA, eds (2007) Obesity: Genomics and Postgenomics.
Informa Healthcare. pp 19–58.
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, et al. (1994) Positional
cloning of the mouse obese gene and its human homologue. Nature 372:
425–432.
3. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN (2003) Meta-
analysis of genetic association studies supports a contribution of common
variants to susceptibility to common disease. Nat Genet 33: 177–182.
4. Clement K, Sørensen TIA, eds (2007) Obesity: Genomics and Postgenomics.
Informa Healthcare. pp 221–228.
5. Peters T, Ausmeier K, Ruther U (1999) Cloning of Fatso (Fto), a novel gene
deleted by the Fused toes (Ft) mouse mutation. Mamm Genome 10: 983–986.
6. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, et al. (2007)
A common variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity. Science 316: 889–894.
7. Dina C, Meyre D, Gallina S, Durand E, Korner A, et al. (2007) Variation in
FTO contributes to childhood obesity and severe adult obesity. Nat Genet 39:
724–726.
8. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, et al. (2007) Genome-Wide
Association Scan Shows Genetic Variants in the FTO Gene Are Associated with
Obesity-Related Traits. PLoS Genet 3: e115.
9. Field SF, Howson JM, Walker NM, Dunger DB, Todd JA (2007) Analysis of the
obesity gene FTO in 14,803 type 1 diabetes cases and controls. Diabetologia 50:
2218–2220.
10. Gerken T, Girard CA, Tung YCL, Webby CJ, Saudek V, et al. (2007) The
Obesity-Associated FTO Gene Encodes a 2-Oxoglutarate-Dependent Nucleic
Acid Demethylase. Science 318: 1469–1472.
11. Black E, Holst C, Astrup A, Toubro S, Echwald S, et al. (2005) Long-term
influences of body-weight changes, independent of the attained weight, on risk of
impaired glucose tolerance and Type 2 diabetes. Diabet Med 22: 1199–1205.
12. Kring SII, Larsen LH, Holst C, Toubro S, Hansen T, et al. (2008) Genotype-
phenotype associations in obesity dependent on definition of the obesity
phenotype. Obesity Facts 1: 138–145.
13. Sonne-Holm S, Sørensen TIA, Jensen G, Schnohr P (1989) Independent effects
of weight change and attained body weight on prevalence of arterial
hypertension in obese and non-obese men. BMJ 299: 767–770.
14. Treuth MS, Hunter GR, Kekes-Szabo T (1995) Estimating intraabdominal
adipose tissue in women by dual-energy X-ray absorptiometry. American
Journal of Clinical Nutrition 62: 527–532.
15. Snijder MB, van Dam RM, Visser M, Seidell JC (2006) What aspects of body fat
are particularly hazardous and how do we measure them? Int J Epidemiol 35:
83–92.
16. Heitmann BL (1994) Impedance: a valid method in assessment of body
composition? Eur J Clin Nutr 48: 228–240.
17. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, et al. (2000)
Use of the oral glucose tolerance test to assess insulin release and insulin
sensitivity. Diabetes Care 23: 295–301.
18. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin clamp.
Diabetes Care 22: 1462–1470.
19. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Volund A, et al. (2007)
The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-
cell function, insulin sensitivity, and glucose tolerance. Diabetes Care 30:
257–262.
20. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M (2001) The
Copenhagen City Heart Study. Tables with data from the third examination
1991–1994. Journal of the European Society of Cardiology 3, Supplement H.
21. Buemann B, Sørensen TIA, Pedersen O, Black E, Holst C, et al. (2005) Lower-
body fat mass as an independent marker of insulin sensitivity-the role of
adiponectin. Int J Obes Relat Metab Disord 29: 624–631.
22. Baker JL, Olsen LW, Sørensen TIA (2007) Childhood Body-Mass Index and the
Risk of Coronary Heart Disease in Adulthood. N Engl J Med 357: 2329–2337.
23. Thomas DC (2004) Statistical Methods in Genetic Epidemiology. Oxford
University Press.
24. Benyamin B, Sørensen TIA, Schousboe K, Fenger M, Visscher PM, et al. (2007)
Are there common genetic and environmental factors behind the endopheno-
types associated with the metabolic syndrome? Diabetologia 50: 1880–1888.
25. Do R, Bailey SD, Desbiens K, Belisle A, Montpetit A, et al. (2008) Genetic
Variants of FTO Influence Adiposity, Insulin Sensitivity, Leptin Levels, and
Resting Metabolic Rate in the Quebec Family Study. Diabetes 57: 1147–1150.
26. Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome.
Nature 444: 881–887.
27. Haslam DW, James WP (2005) Obesity. Lancet 366: 1197–1209.
28. Andreasen CH, Stender-Petersen KL, Mogensen MS, Torekov SS, Wegner L,
et al. (2008) Low Physical Activity Accentuates the Effect of the FTO rs9939609
Polymorphism on Body Fat Accumulation. Diabetes 57: 95–101.
29. Berentzen T, Kring SII, Holst C, Zimmermann E, Jess T, et al. (2008) Lack of
association of fatness-related FTO gene variants with energy expenditure or
physical activity. Journal of Clinical Endocrinology Metabolism E-publication
April 29, 2008, doi:10.1210/jc.2008-0007.
FTO, Fatness and Metabolism
PLoS ONE | www.plosone.org 7 August 2008 | Volume 3 | Issue 8 | e2958